CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: C11orf58 (ImmuneEditome ID:10944)

1. Gene summary of enriched editing regions for C11orf58

check button Gene summary
Gene informationGene symbol

C11orf58

Gene ID

10944

GeneSynonymsIMAGE145052|SMAP
GeneCytomap

11p15.2

GeneTypeprotein-coding
GeneDescriptionsmall acidic protein
GeneModificationdate20230409
UniprotIDE9PRZ9;E9PQA1;E9PM92
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr11:16740501-16740993:+ENST00000525256.1ENSG00000110696.8C11orf58ncRNA_intronicAluY,AluJbchr11:16740501-16740993:+.alignment
chr11:16740501-16740993:+ENST00000527893.4ENSG00000110696.8C11orf58ncRNA_intronicAluY,AluJbchr11:16740501-16740993:+.alignment
chr11:16756290-16756906:+ENST00000524508.1ENSG00000110696.8C11orf58ncRNA_exonicAluSp,AluSc8chr11:16756290-16756906:+.alignment


Top

2. Tumor-specific enriched editing regions for C11orf58


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr11:16756290-16756906:+BRCAEER4.8850e-16image
ENSG00000110696.8,C11orf58BRCAEAG1.1557e-15image
chr11:16756290-16756906:+COADEER1.9466e-02image
ENSG00000110696.8,C11orf58COADEAG2.5922e-02image
chr11:16756290-16756906:+HNSCEER1.4604e-12image
ENSG00000110696.8,C11orf58HNSCEAG1.4617e-12image
chr11:16756290-16756906:+KICHEER3.3290e-02image
ENSG00000110696.8,C11orf58KICHEAG3.3290e-02image
chr11:16756290-16756906:+KIRCEER4.2726e-03image
ENSG00000110696.8,C11orf58KIRCEAG3.8903e-03image
chr11:16756290-16756906:+KIRPEER9.7620e-03image
ENSG00000110696.8,C11orf58KIRPEAG9.7620e-03image
chr11:16756290-16756906:+LUADEER6.1619e-10image
ENSG00000110696.8,C11orf58LUADEAG6.1327e-10image
chr11:16756290-16756906:+LUSCEER4.4979e-06image
ENSG00000110696.8,C11orf58LUSCEAG4.3686e-06image
chr11:16756290-16756906:+PRADEER2.8868e-03image
ENSG00000110696.8,C11orf58PRADEAG2.9956e-03image
chr11:16756290-16756906:+THCAEER5.3612e-12image
ENSG00000110696.8,C11orf58THCAEAG5.4516e-12image
chr11:16756290-16756906:+UCECEER1.9429e-05image
ENSG00000110696.8,C11orf58UCECEAG1.6523e-05image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000110696.8,C11orf58KIRCPathEAG4.2673e-021.0110e-020.1116image
chr11:16756290-16756906:+KIRCPathEER4.3965e-021.0347e-020.1113image
ENSG00000110696.8,C11orf58LIHCPathEAG2.4517e-022.1923e-03-0.1661image
chr11:16756290-16756906:+LIHCPathEER2.4517e-022.1923e-03-0.1661image
ENSG00000110696.8,C11orf58TGCTPathEAG3.1007e-029.1962e-03-0.2895image
chr11:16756290-16756906:+TGCTPathEER3.1007e-029.1962e-03-0.2895image
ENSG00000110696.8,C11orf58THCAPathEAG1.6379e-049.0564e-040.1477image
chr11:16756290-16756906:+THCAPathEER1.6198e-048.8674e-040.1479image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for C11orf58


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr11:16756290-16756906:+KICHEERENSG00000138756,BMP2K-0.58901.7536e-029.4035e-05-0.4653imageNNNAB_cells_naiveGSVA_HALLMARK_UV_RESPONSE_DN
chr11:16756290-16756906:+KICHEERENSG00000165392,WRN-0.55712.3602e-022.6682e-05-0.4958imageNNWRNNK_cells_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
chr11:16756290-16756906:+KICHEERENSG00000185728,YTHDF3-0.55432.5241e-026.6531e-06-0.5265imageNNNAB_cells_naiveGSVA_HALLMARK_PROTEIN_SECRETION
chr11:16756290-16756906:+KICHEERENSG00000215301,DDX3X-0.53542.9530e-023.2507e-04-0.4321imageNNDDX3XB_cells_naiveGSVA_HALLMARK_UV_RESPONSE_DN
chr11:16756290-16756906:+KICHEERENSG00000018610,CXorf56-0.54113.0596e-023.1996e-05-0.4916imageNNNADendritic_cells_activatedGSVA_HALLMARK_MYC_TARGETS_V1
chr11:16756290-16756906:+KICHEERENSG00000104331,IMPAD1-0.52823.2341e-021.1896e-04-0.4593imageNNNAGSVA_HALLMARK_ANDROGEN_RESPONSE
chr11:16756290-16756906:+KICHEERENSG00000136986,DERL1-0.51763.2341e-027.3179e-05-0.4716imageNNDERL1MonocytesGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
chr11:16756290-16756906:+KICHEERENSG00000083168,KAT6A-0.53903.2648e-025.6382e-06-0.5299imageNNKAT6AB_cells_naiveGSVA_HALLMARK_UV_RESPONSE_DN
chr11:16756290-16756906:+KICHEERENSG00000138660,AP1AR-0.54453.3251e-023.7284e-05-0.4880imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
chr11:16756290-16756906:+KICHEERENSG00000118620,ZNF430-0.53403.4714e-021.4386e-04-0.4543imageNNNAB_cells_naiveGSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

4. Enriched editing regions and immune related splicing for C11orf58


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr11:16756290-16756906:+
CESCEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.43735.4218e-107.0667e-15-0.4312imageNNPRKCSHMacrophages_M0GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000110696.8,C11orf58
CESCEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.43654.0572e-109.5674e-15-0.4293imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184PRKCSHMacrophages_M0GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000110696.8,C11orf58
STADEAGIRENSG00000163257.6chr417800654:17804771:17805106:17805225-0.43994.3857e-129.5650e-14-0.4026imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAMacrophages_M2GSVA_HALLMARK_HEME_METABOLISM
ENSG00000110696.8,C11orf58
STADEAGIRENSG00000168137.11chr39464424:9468575:9470458:9470929-0.35506.8935e-093.2076e-12-0.4095imageNACIN1;AIFM1;ALKBH5;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAB_cells_memoryGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000110696.8,C11orf58
STADEAGIRENSG00000168137.11chr39464409:9464672:9468518:9468575-0.39312.9221e-101.9601e-13-0.4140imageNACIN1;AIFM1;ALKBH5;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAB_cells_memoryGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000110696.8,C11orf58
STADEAGIRENSG00000163257.6chr417804311:17804756:17805106:17805225-0.39703.0140e-102.3126e-13-0.4052imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NANK_cells_activatedGSVA_HALLMARK_HEME_METABOLISM
ENSG00000110696.8,C11orf58
STADEAGIRENSG00000100325.10chr2229832244:29832342:29834441:29834550-0.35713.0503e-108.1184e-14-0.4468imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMacrophages_M2GSVA_HALLMARK_UV_RESPONSE_UP
chr11:16756290-16756906:+
TGCTEERIRENSG00000168010.6chr1172822340:72824122:72824733:72824842-0.29961.1150e-029.8615e-07-0.4124imageNNNAMacrophages_M2GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr11:16756290-16756906:+
TGCTEERESENSG00000171302.12chr1778997839:78997963:78998147:79000270:79009663:790097300.26882.9274e-022.2220e-060.4013imageNNNAMacrophages_M2GSVA_HALLMARK_ANGIOGENESIS
chr11:16756290-16756906:+
TGCTEERA3ENSG00000008838.13chr1740054360:40054375:40053468:40053635:40053468:40053768-0.31534.6863e-035.0470e-07-0.4380imageNNNAMacrophages_M2GSVA_HALLMARK_TGF_BETA_SIGNALING

More results



Top

5. Enriched editing regions and immune infiltration for C11orf58


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr11:16756290-16756906:+BLCAEERT_cells_CD4_memory_activated1.2949e-080.2830image
ENSG00000110696.8,C11orf58BLCAEAGT_cells_CD4_memory_activated9.7181e-090.2853image
chr11:16756290-16756906:+BRCAEERMacrophages_M14.9582e-060.1392image
ENSG00000110696.8,C11orf58BRCAEAGMacrophages_M13.0905e-070.1553image
chr11:16756290-16756906:+CESCEERMacrophages_M01.8141e-04-0.2156image
ENSG00000110696.8,C11orf58CESCEAGMacrophages_M02.0084e-04-0.2141image
chr11:16756290-16756906:+CHOLEERT_cells_regulatory_(Tregs)2.4114e-020.3861image
ENSG00000110696.8,C11orf58CHOLEAGT_cells_regulatory_(Tregs)2.4006e-020.3864image
chr11:16756290-16756906:+COADEERMacrophages_M13.0197e-040.2211image
ENSG00000110696.8,C11orf58COADEAGMacrophages_M11.0014e-030.2006image
chr11:16740501-16740993:+ESCAEERNK_cells_activated2.6644e-020.2274image
chr11:16756290-16756906:+GBMEERMacrophages_M03.6387e-05-0.3156image
ENSG00000110696.8,C11orf58GBMEAGMacrophages_M03.6387e-05-0.3156image
chr11:16756290-16756906:+HNSCEERMacrophages_M13.7221e-070.2274image
ENSG00000110696.8,C11orf58HNSCEAGMacrophages_M13.7176e-070.2274image
chr11:16756290-16756906:+KICHEERB_cells_memory3.0176e-020.2691image
ENSG00000110696.8,C11orf58KICHEAGB_cells_memory3.0176e-020.2691image
chr11:16756290-16756906:+KIRCEERT_cells_gamma_delta2.1798e-070.2608image
ENSG00000110696.8,C11orf58KIRCEAGT_cells_gamma_delta1.7209e-070.2629image
chr11:16756290-16756906:+KIRPEERPlasma_cells2.5836e-02-0.1325image
ENSG00000110696.8,C11orf58KIRPEAGPlasma_cells2.5836e-02-0.1325image
chr11:16740501-16740993:+LAMLEERPlasma_cells5.1811e-030.2448image
ENSG00000110696.8,C11orf58LAMLEAGMacrophages_M01.2987e-020.2157image
chr11:16756290-16756906:+LGGEERT_cells_CD4_memory_activated5.9540e-040.1488image
ENSG00000110696.8,C11orf58LGGEAGT_cells_CD4_memory_activated2.4887e-030.1312image
chr11:16756290-16756906:+LIHCEERMacrophages_M01.2278e-03-0.1695image
ENSG00000110696.8,C11orf58LIHCEAGMacrophages_M01.2278e-03-0.1695image
chr11:16756290-16756906:+LUADEERT_cells_CD4_memory_activated1.9742e-030.1385image
ENSG00000110696.8,C11orf58LUADEAGT_cells_CD4_memory_activated1.9874e-030.1384image
chr11:16756290-16756906:+LUSCEERT_cells_CD4_memory_activated5.7733e-050.1812image
ENSG00000110696.8,C11orf58LUSCEAGT_cells_CD4_memory_activated6.2220e-050.1804image
chr11:16756290-16756906:+MESOEERB_cells_naive1.2103e-02-0.2776image
ENSG00000110696.8,C11orf58MESOEAGB_cells_naive1.2103e-02-0.2776image
chr11:16756290-16756906:+OVEERMacrophages_M23.3593e-020.1287image
ENSG00000110696.8,C11orf58OVEAGMacrophages_M21.6557e-020.1447image
chr11:16756290-16756906:+PAADEERNK_cells_resting3.4929e-020.1600image
ENSG00000110696.8,C11orf58PAADEAGNK_cells_resting3.4581e-020.1603image
chr11:16756290-16756906:+PCPGEERNK_cells_activated1.9896e-020.1725image
ENSG00000110696.8,C11orf58PCPGEAGNK_cells_activated1.9862e-020.1725image
chr11:16756290-16756906:+PRADEERT_cells_CD4_naive8.8627e-040.1484image
ENSG00000110696.8,C11orf58PRADEAGT_cells_CD4_naive8.4467e-040.1490image
chr11:16756290-16756906:+READEERT_cells_follicular_helper1.2520e-02-0.2567image
ENSG00000110696.8,C11orf58READEAGT_cells_follicular_helper1.2520e-02-0.2567image
chr11:16756290-16756906:+SARCEERMacrophages_M19.8926e-030.1616image
ENSG00000110696.8,C11orf58SARCEAGMacrophages_M19.8926e-030.1616image
chr11:16756290-16756906:+SKCMEERT_cells_CD85.8971e-070.2336image
ENSG00000110696.8,C11orf58SKCMEAGT_cells_CD85.0239e-070.2350image
chr11:16740501-16740993:+STADEERNeutrophils2.6891e-02-0.1632image
chr11:16756290-16756906:+STADEERMacrophages_M21.0648e-020.1475image
ENSG00000110696.8,C11orf58STADEAGT_cells_CD4_memory_activated3.9721e-030.1614image
chr11:16756290-16756906:+TGCTEERMacrophages_M21.5356e-06-0.3761image
ENSG00000110696.8,C11orf58TGCTEAGMacrophages_M21.5356e-06-0.3761image
chr11:16756290-16756906:+THCAEERT_cells_regulatory_(Tregs)6.5595e-060.1994image
ENSG00000110696.8,C11orf58THCAEAGT_cells_regulatory_(Tregs)6.0479e-060.2002image
chr11:16756290-16756906:+THYMEERMacrophages_M11.3232e-050.3924image
ENSG00000110696.8,C11orf58THYMEAGMacrophages_M11.3232e-050.3924image
chr11:16756290-16756906:+UCECEERT_cells_CD4_memory_resting4.1925e-02-0.1549image
ENSG00000110696.8,C11orf58UCECEAGT_cells_CD82.7984e-020.1666image
chr11:16756290-16756906:+UCSEEREosinophils4.3160e-02-0.2712image
ENSG00000110696.8,C11orf58UCSEAGEosinophils4.3696e-02-0.2706image
chr11:16756290-16756906:+UVMEERT_cells_CD4_memory_resting3.7236e-02-0.2495image
ENSG00000110696.8,C11orf58UVMEAGT_cells_CD4_memory_resting3.7236e-02-0.2495image


Top

6. Enriched editing regions and immune gene sets for C11orf58


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr11:16756290-16756906:+BLCAEER1.6848e-040.18948.5536e-040.16821.6348e-030.15905.2488e-030.1411image
ENSG00000110696.8,C11orf58BLCAEAG1.3913e-040.19178.4334e-040.16841.4072e-030.16114.0091e-030.1454image
ENSG00000110696.8,C11orf58STADEAG7.9146e-040.18756.2334e-030.15332.8813e-030.16691.7844e-040.2090image
chr11:16756290-16756906:+THYMEER1.3627e-02-0.22851.4119e-03-0.29307.8140e-030.24586.5404e-060.4049image
ENSG00000110696.8,C11orf58THYMEAG1.3627e-02-0.22851.4119e-03-0.29307.8140e-030.24586.5404e-060.4049image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr11:16756290-16756906:+ACCGSVA_HALLMARK_NOTCH_SIGNALINGEER1.5530e-03-0.3546image
ENSG00000110696.8,C11orf58ACCGSVA_HALLMARK_NOTCH_SIGNALINGEAG1.5530e-03-0.3546image
chr11:16756290-16756906:+BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.1797e-090.2877image
ENSG00000110696.8,C11orf58BLCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.2660e-090.2902image
chr11:16756290-16756906:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.2232e-220.2876image
ENSG00000110696.8,C11orf58BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.1912e-230.2973image
chr11:16756290-16756906:+CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER4.5709e-070.2877image
ENSG00000110696.8,C11orf58CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG4.5481e-070.2877image
chr11:16756290-16756906:+CHOLGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER1.8801e-02-0.4009image
ENSG00000110696.8,C11orf58CHOLGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.8836e-02-0.4008image
chr11:16756290-16756906:+COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.7732e-050.2554image
ENSG00000110696.8,C11orf58COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.1227e-050.2524image
chr11:16756290-16756906:+DLBCGSVA_HALLMARK_E2F_TARGETSEER4.4046e-03-0.4081image
ENSG00000110696.8,C11orf58DLBCGSVA_HALLMARK_E2F_TARGETSEAG4.4046e-03-0.4081image
chr11:16740501-16740993:+ESCAGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER7.5156e-030.2726image
ENSG00000110696.8,C11orf58ESCAGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG4.8587e-030.2273image
chr11:16756290-16756906:+ESCAGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.1458e-02-0.2095image
ENSG00000110696.8,C11orf58GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.3849e-080.4177image
chr11:16756290-16756906:+GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.3849e-080.4177image
chr11:16756290-16756906:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.3065e-160.3623image
ENSG00000110696.8,C11orf58HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.2978e-160.3623image
ENSG00000110696.8,C11orf58KICHGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.0057e-05-0.5177image
chr11:16756290-16756906:+KICHGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.0057e-05-0.5177image
ENSG00000110696.8,C11orf58KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG7.0463e-060.2270image
chr11:16756290-16756906:+KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER6.4061e-060.2280image
ENSG00000110696.8,C11orf58KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.4055e-05-0.2482image
chr11:16756290-16756906:+KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER2.4055e-05-0.2482image
ENSG00000110696.8,C11orf58LAMLGSVA_HALLMARK_PEROXISOMEEAG9.1608e-04-0.2852image
chr11:16740501-16740993:+LAMLGSVA_HALLMARK_PEROXISOMEEER8.5759e-04-0.2900image
chr11:16756290-16756906:+LGGGSVA_HALLMARK_SPERMATOGENESISEER3.9807e-10-0.2676image
ENSG00000110696.8,C11orf58LGGGSVA_HALLMARK_SPERMATOGENESISEAG3.4449e-10-0.2685image
ENSG00000110696.8,C11orf58LIHCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG6.0051e-100.3184image
chr11:16756290-16756906:+LIHCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER6.0051e-100.3184image
chr11:16756290-16756906:+LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.9184e-080.2416image
ENSG00000110696.8,C11orf58LUADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.0034e-080.2415image
chr11:16756290-16756906:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.1299e-060.2185image
ENSG00000110696.8,C11orf58LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.2934e-060.2173image
chr11:16756290-16756906:+OVGSVA_HALLMARK_HEME_METABOLISMEER7.9311e-050.2365image
chr11:16740501-16740993:+OVGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER3.6458e-020.2505image
ENSG00000110696.8,C11orf58OVGSVA_HALLMARK_HEME_METABOLISMEAG1.3213e-050.2598image
chr11:16756290-16756906:+PAADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.9384e-040.2713image
ENSG00000110696.8,C11orf58PAADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.8178e-040.2720image
chr11:16756290-16756906:+PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEER9.8212e-05-0.2847image
ENSG00000110696.8,C11orf58PCPGGSVA_HALLMARK_MITOTIC_SPINDLEEAG9.2915e-05-0.2856image
chr11:16756290-16756906:+PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.8121e-050.1790image
ENSG00000110696.8,C11orf58PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.9580e-050.1806image
chr11:16756290-16756906:+READGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.7813e-020.2270image
ENSG00000110696.8,C11orf58READGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.7813e-020.2270image
ENSG00000110696.8,C11orf58SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.3179e-020.1554image
chr11:16756290-16756906:+SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.3179e-020.1554image
chr11:16756290-16756906:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.7731e-070.2375image
ENSG00000110696.8,C11orf58SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.2377e-070.2388image
chr11:16756290-16756906:+STADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER1.8862e-040.2143image
ENSG00000110696.8,C11orf58STADGSVA_HALLMARK_HEME_METABOLISMEAG5.5531e-070.2768image
chr11:16740501-16740993:+STADGSVA_HALLMARK_P53_PATHWAYEER3.9150e-030.2117image
ENSG00000110696.8,C11orf58TGCTGSVA_HALLMARK_GLYCOLYSISEAG6.9723e-06-0.3533image
chr11:16756290-16756906:+TGCTGSVA_HALLMARK_GLYCOLYSISEER6.9723e-06-0.3533image
ENSG00000110696.8,C11orf58THCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.6175e-130.3152image
chr11:16756290-16756906:+THCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.3707e-130.3155image
chr11:16756290-16756906:+THYMGSVA_HALLMARK_HYPOXIAEER6.5404e-060.4049image
ENSG00000110696.8,C11orf58THYMGSVA_HALLMARK_HYPOXIAEAG6.5404e-060.4049image
chr11:16756290-16756906:+UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.6041e-040.2511image
ENSG00000110696.8,C11orf58UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.5583e-030.2273image
ENSG00000110696.8,C11orf58UCSGSVA_HALLMARK_MYOGENESISEAG9.9892e-03-0.3415image
chr11:16756290-16756906:+UCSGSVA_HALLMARK_MYOGENESISEER9.6181e-03-0.3432image
ENSG00000110696.8,C11orf58UVMGSVA_HALLMARK_APICAL_SURFACEEAG1.2209e-030.3788image
chr11:16756290-16756906:+UVMGSVA_HALLMARK_APICAL_SURFACEEER1.2209e-030.3788image


Top

7. Enriched editing regions and drugs for C11orf58


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000110696.8,C11orf58ACCGemcitabineEAG8.3656e-040.3729image
chr11:16756290-16756906:+ACCGemcitabineEER8.3656e-040.3729image
chr11:16756290-16756906:+BLCAEHT.1864EER4.1757e-060.2306image
ENSG00000110696.8,C11orf58BLCAEHT.1864EAG3.9040e-060.2313image
ENSG00000110696.8,C11orf58BRCAA.443654EAG6.6105e-09-0.1757image
chr11:16756290-16756906:+BRCAA.443654EER2.2987e-07-0.1574image
chr11:16756290-16756906:+CESCCI.1040EER1.6386e-04-0.2170image
ENSG00000110696.8,C11orf58CESCCI.1040EAG1.8994e-04-0.2149image
chr11:16756290-16756906:+CHOLElesclomolEER1.4029e-02-0.4175image
ENSG00000110696.8,C11orf58CHOLElesclomolEAG1.4050e-02-0.4174image
chr11:16756290-16756906:+COADAICAREER8.8407e-05-0.2394image
ENSG00000110696.8,C11orf58COADAICAREAG4.9622e-03-0.1718image
chr11:16756290-16756906:+DLBCAZD.2281EER5.9576e-03-0.3953image
ENSG00000110696.8,C11orf58DLBCAZD.2281EAG5.9576e-03-0.3953image
chr11:16740501-16740993:+ESCAABT.263EER1.5286e-020.2495image
ENSG00000110696.8,C11orf58ESCAAxitinibEAG2.2768e-03-0.2465image
chr11:16756290-16756906:+ESCAAxitinibEER2.6043e-04-0.2999image
chr11:16756290-16756906:+GBMBMS.754807EER5.7989e-070.3775image
ENSG00000110696.8,C11orf58GBMBMS.754807EAG5.7989e-070.3775image
chr11:16756290-16756906:+HNSCFH535EER1.3382e-090.2698image
ENSG00000110696.8,C11orf58HNSCFH535EAG1.3396e-090.2698image
ENSG00000110696.8,C11orf58KICHEmbelinEAG1.8645e-020.2911image
chr11:16756290-16756906:+KICHEmbelinEER1.8645e-020.2911image
ENSG00000110696.8,C11orf58KIRCCisplatinEAG2.6302e-09-0.2978image
chr11:16756290-16756906:+KIRCCisplatinEER2.0337e-09-0.2998image
chr11:16756290-16756906:+KIRPAZD6482EER9.1515e-060.2603image
ENSG00000110696.8,C11orf58KIRPAZD6482EAG9.1515e-060.2603image
ENSG00000110696.8,C11orf58LAMLGDC0941EAG8.0108e-03-0.2299image
chr11:16740501-16740993:+LAMLGDC0941EER1.2111e-02-0.2203image
chr11:16756290-16756906:+LGGBexaroteneEER1.2346e-14-0.3268image
ENSG00000110696.8,C11orf58LGGBexaroteneEAG9.6757e-15-0.3281image
chr11:16756290-16756906:+LIHCBMS.754807EER3.6055e-120.3560image
ENSG00000110696.8,C11orf58LIHCBMS.754807EAG3.6055e-120.3560image
ENSG00000110696.8,C11orf58LUADCCT007093EAG3.7637e-030.1297image
chr11:16756290-16756906:+LUADCCT007093EER3.7506e-030.1298image
ENSG00000110696.8,C11orf58LUSCAZD.2281EAG5.0609e-04-0.1572image
chr11:16756290-16756906:+LUSCAZD.2281EER4.9155e-04-0.1575image
ENSG00000110696.8,C11orf58MESOCytarabineEAG9.7110e-030.2858image
chr11:16756290-16756906:+MESOCytarabineEER9.7110e-030.2858image
chr11:16756290-16756906:+OVGDC0941EER7.9250e-04-0.2019image
chr11:16740501-16740993:+OVBortezomibEER3.0151e-02-0.2594image
ENSG00000110696.8,C11orf58OVGDC0941EAG1.4617e-03-0.1913image
ENSG00000110696.8,C11orf58PAADBexaroteneEAG3.3637e-03-0.2211image
chr11:16756290-16756906:+PAADBexaroteneEER3.3257e-03-0.2214image
ENSG00000110696.8,C11orf58PCPGFH535EAG2.7091e-030.2211image
chr11:16756290-16756906:+PCPGFH535EER2.7689e-030.2206image
chr11:16756290-16756906:+PRADMethotrexateEER1.1740e-06-0.2162image
ENSG00000110696.8,C11orf58PRADMethotrexateEAG1.2513e-06-0.2156image
chr11:16756290-16756906:+READAZD.0530EER2.8299e-02-0.2275image
ENSG00000110696.8,C11orf58READAZD.0530EAG2.8299e-02-0.2275image
chr11:16756290-16756906:+SARCAKT.inhibitor.VIIIEER5.6682e-04-0.2148image
ENSG00000110696.8,C11orf58SARCAKT.inhibitor.VIIIEAG5.6682e-04-0.2148image
ENSG00000110696.8,C11orf58SKCMDMOGEAG4.0998e-06-0.2159image
chr11:16756290-16756906:+SKCMDMOGEER4.1257e-06-0.2158image
chr11:16740501-16740993:+STADFH535EER3.3040e-03-0.2155image
chr11:16756290-16756906:+STADBMS.509744EER3.3275e-03-0.1693image
ENSG00000110696.8,C11orf58STADBMS.509744EAG1.5683e-03-0.1769image
ENSG00000110696.8,C11orf58TGCTBMS.754807EAG6.3153e-050.3166image
chr11:16756290-16756906:+TGCTBMS.754807EER6.3153e-050.3166image
ENSG00000110696.8,C11orf58THCACI.1040EAG5.1210e-23-0.4209image
chr11:16756290-16756906:+THCACI.1040EER5.0100e-23-0.4210image
chr11:16756290-16756906:+THYMABT.263EER2.0920e-080.4916image
ENSG00000110696.8,C11orf58THYMABT.263EAG2.0920e-080.4916image
chr11:16756290-16756906:+UCECFH535EER2.6668e-040.2738image
ENSG00000110696.8,C11orf58UCECFH535EAG6.6850e-050.2975image
ENSG00000110696.8,C11orf58UCSBryostatin.1EAG1.5009e-03-0.4143image
chr11:16756290-16756906:+UCSBryostatin.1EER1.3376e-03-0.4183image
chr11:16756290-16756906:+UVMBexaroteneEER3.8158e-04-0.4129image
ENSG00000110696.8,C11orf58UVMBexaroteneEAG3.8158e-04-0.4129image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType